Dr. Billy Loo is a distinguished Professor of Radiation Oncology at Stanford University and serves as Director of Thoracic Radiation Oncology and Co-director of Particle Therapy. He holds additional affiliations as a member of the Stanford Cancer Institute, the Molecular Imaging Program at Stanford, and Bio-X, reflecting his interdisciplinary expertise. Dr. Loo earned his MD from University of California Davis and PhD in Bioengineering from University of California San Francisco and Berkeley, completing his Radiation Oncology residency training at Stanford. His clinical expertise centers on precision targeted radiotherapy for lung and thoracic cancers, positioning him as a leading authority in this specialized field. His dual training as both a physician and bioengineer forms the foundation of his innovative approach to cancer treatment.
Dr. Loo is Principal Investigator of the groundbreaking FLASH Sciences Lab at Stanford, where his research focuses on developing ultra-rapid FLASH radiotherapy to optimize the biological therapeutic index of cancer treatment. He co-invented a revolutionary approach to delivering radiation therapy called pluridirectional high-energy agile scanning electronic radiotherapy (PHASER), which represents a fundamental advance in precision radiation delivery. His laboratory work bridges basic science with clinical applications through collaboration between the Stanford Cancer Institute and SLAC National Accelerator Laboratory. His research has expanded the applications of stereotactic ablative radiotherapy beyond cancer to treat conditions such as pulmonary emphysema and cardiac arrhythmias, demonstrating the versatility of precision radiation techniques.
As Vice Chair of the National Comprehensive Cancer Network Small Cell Lung Cancer Panel since 2013, Dr. Loo has shaped national treatment guidelines and clinical standards. He actively leads the translation of advanced radiation technologies from the laboratory to clinical practice, emphasizing the practical implementation of high-precision 4-D image-guided radiotherapy. His work developing novel functional and metabolic imaging techniques for measuring organ function and predicting treatment response has advanced personalized cancer care. Through his leadership in both academic and entrepreneurial settings, including as Founder and Chief Medical Advisor of TibaRay, Dr. Loo continues to pioneer innovations that transform radiation oncology practice and improve patient outcomes worldwide.
